H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Urogen Pharma Ltd (URGN) today and set a price target of $75. The company’s shares closed on Friday at $36.52, close to its 52-week low of $34.61.

Selvaraju noted: “We reiterate our Buy rating and 12-month target of $75 per share on URGN.”

According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -3.0% and a 29.9% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.

Currently, the analyst consensus on Urogen Pharma Ltd is a Strong Buy with an average price target of $66.25.

The company has a one-year high of $61.93 and a one-year low of $34.61. Currently, Urogen Pharma Ltd has an average volume of 122.5K.

Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of URGN in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocksare most likely to make moves following their insider activities.

UroGen Pharma Ltd. is a clinical stage pharmaceutical company, which engages in the provision of non-surgical and localized solutions for urological pathologies to address a clinical unmet need in field of uro-oncology.